TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04274413

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Beta Adrenergic Sweat Test
Description: In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab.~1. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site.~2. Under the first probe, injection atropine will be given in one small area of the skin.~3. Under the second probe, first injection carbachol will be given in one small area of the skin.~4. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine.~5. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded.
Study: NCT05981898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTIVF dosage
Description: Dosage predicted by Opt-IVf

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional Dosage
Description: Dosage used traditionally by doctors
Study: NCT05530759

Intervention type: PROCEDURE
Intervention: Biopsy Specimen
Description: Undergo collection of tissue samples

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and buccal swab samples

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of archived tissue and blood samples

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical record
Study: NCT05925504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
Study: NCT05507593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLL3-CAR-NK cells
Description: Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
Study: NCT06718829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: All patients will undergo a traditional physical therapy program consisting of stretching exercises, strengthening exercises, and scar management techniques, three times weekly for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: All patients will undergo a traditional physical therapy program consisting of stretching exercises, strengthening exercises, and scar management techniques, three times weekly for eight weeks.
Study: NCT06719323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Walking Instruction with Support by Heart (Family WISH) program
Description: Researchers will compare the 12-week Family WISH program, based on self-efficacy theory, to a comparison group receiving a family walking health education sheet to evaluate the long-term effectiveness of the Family WISH program.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Comparison group
Description: a family walking health education sheet received
Study: NCT06719310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACC017+FTC/TAF
Description: ACC017+FTC/TAF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACC017+FTC/TAF
Description: ACC017+FTC/TAF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACC017+FTC/TAF
Description: ACC017+FTC/TAF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06714994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: free spectacles
Description: Children will receive free spectacles
Study: NCT06717074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD4059
Description: RBD4059, active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD4059
Description: RBD4059, active drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo that is identical in appearance and volume to the doses of active IMP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo that is identical in appearance and volume to the doses of active IMP.
Study: NCT06716086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shape memory alloy-based orthosis
Description: The home program with the shape memory alloy-based orthosis contains warm-up part and correction part. The SMA-based orthosis is an improvement over traditional dynamic splint. This corrective device uses shape memory alloy as an elastic component specifically designed to address finger joint stiffness. It provides continuous force for stiff joint in order to address stiffness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional stretching program
Description: The home program for the stretching group includes active joint range of motion exercises and passive stretching exercises. Participants will follow instructions to perform various joint movements, with a focus on their restricted fingers.
Study: NCT06718660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Educational Nursing program
Description: The intervention is a structured educational program designed to enhance nursing competence in biomedical waste management at El-Minia University Hospital. It was developed based on evidence-based guidelines, national and international standards, and a detailed assessment of baseline knowledge and practices among the participating nurses.
Study: NCT06718946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFE
Description: Intravenous administration of oncolytic virus every 3 weeks until tumor progression
Study: NCT06715007

Intervention type: DRUG
Intervention: Clopidogrel
Description: Patients will take Clopidogrel

Intervention type: DRUG
Intervention: Clopidogrel
Description: Patients will take Clopidogrel

Intervention type: DRUG
Intervention: Aspirin
Description: Patients will take Rivaroxaban

Intervention type: DRUG
Intervention: Aspirin
Description: Patients will take Rivaroxaban

Intervention type: DRUG
Intervention: Cilostazol + Isosorbide Mononitrate
Description: Patients will take Cilostazol plus Isosorbide Mononitrate

Intervention type: DRUG
Intervention: Cilostazol + Isosorbide Mononitrate
Description: Patients will take Cilostazol plus Isosorbide Mononitrate
Study: NCT06717919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion
Description: All study centres will use either VitaSmart, Liver assist or Perlife devices for machine liver perfusion, with a pressure controlled hypothermic oxygenated liver perfusion through the portal vein (HOPE) or through the portal vein and the hepatic artery (DHOPE), targeting a flow rate between 200-250 ml/min at a pressure of 3 mmHg, and a perfusate temperature between 8-12°C. The perfusate consists of 3L re-circulating Belzer MPS® (Bridge to Life Ltd.) with an active oxygenation (70-110 kPa). The minimum perfusion duration is defined at 2 hours, while perfusion is generally continued until the recipient hepatectomy is completed. The perfusion will exclusively be performed in the recipient centre after initial cold storage and bench preparation of the liver for implantation. The perfusion devices are routinely used in all participating centres.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold storage
Description: Conventional cold storage at 4°C will be performed with precooled preservation solution according to local standard of care. For cold storage at the Swiss centres, IGL-1 (Institute George Lopez) is used for cold storage. Liver transplant centres in other European countries, use mainly three other storage solutions (Histidine trypophan-ketoglutarat, HTK and University of Wisconsin, UW solution, Celsior) in accordance to their national guidelines.
Study: NCT06014216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavoured ice lollies (popsicles)
Description: Blackcurrant flavoured ice popsicles, 105ml volume.

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Water from tap, one cup given by recovery nurses.
Study: NCT06715449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day in addition to their usual stroke care.
Study: NCT06718153

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry and in situ hybridisation analysis
Description: immunohistochemistry and in situ hybridisation analysis for several markers, including p53, beta-Catenin and albumin, but also markers considered diagnostic for HCC such as Glutamin Synthetase, Glypican-3 and HSP70, to identify a more rational diagnostic-prognostic algorithm for primary liver lesions.
Study: NCT06716112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) Device
Description: All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers active VNS stimulation.
Study: NCT05507593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLL3-CAR-NK cells
Description: Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLL3-CAR-NK cells
Description: Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
Study: NCT06716112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) Device
Description: All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers active VNS stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham VNS Device
Description: All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers sham VNS stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham VNS Device
Description: All patients will be implanted with the ReStore VNS device by an NYU neurosurgeon. During treatment sessions, study personnel will deliver a VNS burst at the completion of a training movement by pressing a button on a smart device, which wirelessly triggers sham VNS stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper Extremity Rehabilitation
Description: Rehabilitation training will be functional and activity-based, focusing on six task categories: reaching and grasping objects, gross movements with objects, flipping objects, inserting objects, self-feeding, and opening and closing containers.~Three 90-minute training sessions per week will be administered by a licensed occupational therapist, over two six-week treatment blocks. Sessions will be paired with either active or sham VNS administration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper Extremity Rehabilitation
Description: Rehabilitation training will be functional and activity-based, focusing on six task categories: reaching and grasping objects, gross movements with objects, flipping objects, inserting objects, self-feeding, and opening and closing containers.~Three 90-minute training sessions per week will be administered by a licensed occupational therapist, over two six-week treatment blocks. Sessions will be paired with either active or sham VNS administration.
Study: NCT06716814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa
Description: Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.
Study: NCT06718959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the test product (Jet Floss EX)
Description: subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add used the test product (Jet Floss EX) twice a day. Subjects used the test product (standard sprinkler, water twice) to flush all gingival margins and adjacent spaces with 440ml of water, start with water pressure gear 1 for the first time and continued with this gear after reaching the highest level that can be asapted. If felt uncomfortable, eligible subjects can adjust it to a suitable gear. The specific installation and usage of the teeth punch refer to the product instruction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the control product (interdental brush)
Description: subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add auxiliary product (interdental brush) twice a day.
Study: NCT05281913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational Game
Description: Psychoeducational Game
Study: NCT04624100

Intervention type: PROCEDURE
Intervention: Hernia repair
Description: Primary or mesh repair of primary ventral or incisional hernia
Study: NCT06499727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Study: NCT06198075

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted.
Study: NCT05663242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
Study: NCT06341387

Intervention type: OTHER
Intervention: Breath, urine and blood analysis
Description: breath sampling: all subjects exhale into two sterile Tedlar bags, connected to a mouthpiece, in a condition similar to traditional spirometry.~Urine will be collected usual urine container.~The blood sample (\~ 5 ml) will be taken with a serum separator tube.

Intervention type: OTHER
Intervention: Breath, urine and blood analysis
Description: breath sampling: all subjects exhale into two sterile Tedlar bags, connected to a mouthpiece, in a condition similar to traditional spirometry.~Urine will be collected usual urine container.~The blood sample (\~ 5 ml) will be taken with a serum separator tube.
Study: NCT06223048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX-2011P
Description: AMDX-2011P single bolus injection intravenous for diagnostic review

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMDX-2011P
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Study: NCT05239013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Description: 2 cm (30mg) of 2% nitroglycerin applied 2 cm from the styloid process of the anterior forearm
Study: NCT05758480

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample (at inclusion and 6 months later)
Description: (56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample (at inclusion and 6 months later)
Description: (56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient questionnaires (at inclusion and 6 months later)
Description: (4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient questionnaires (at inclusion and 6 months later)
Description: (4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.
Study: NCT04306237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-1018972
Description: IMB-1018972 200 mg tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matched placebo tablet for oral administration
Study: NCT06013137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therabot
Description: The participants assigned to the experimental group will interact with an artificial intelligence therapy chatbot to alleviate symptoms associated with depression, anxiety, and eating disorders. The control group will not have access to this smartphone chatbot app.
Study: NCT05072197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile device as a support tool for the treatment of women with breast cancer undergoing chemotherapy
Description: This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers.
Study: NCT06394375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: OFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Given as analgesia in opioid balanced anesthesia (control) group
Study: NCT04798118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: toilet bronchoscope
Description: Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: toilet bronchoscope
Description: Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
Study: NCT05476107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-126
Description: Single or daily dosing at doses A, B, C, D, E, F; G, H, and I

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or daily dosing at doses A, B, C, D, E, F; G,H, and I

Intervention type: OTHER
Group type: OTHER
Intervention: Radioactive Tablet (Part 2 Only)
Description: Single dose in two periods in Part 2 (optional)
Study: NCT05043623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinoswab Junior
Description: Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinoswab Junior
Description: Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinoswab Junior
Description: Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined nose and throat swab
Description: Combined nose and throat swab (standard of care)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined nose and throat swab
Description: Combined nose and throat swab (standard of care)
Study: NCT05097248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT05900921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: IV infusion, d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion, d1